Granisetron
- Generic Name
- Granisetron
- Brand Names
- Sancuso, Sustol
- Drug Type
- Small Molecule
- Chemical Formula
- C18H24N4O
- CAS Number
- 109889-09-0
- Unique Ingredient Identifier
- WZG3J2MCOL
- Background
A serotonin receptor (5HT-3 selective) antagonist that has been used as an antiemetic and antinauseant for cancer chemotherapy patients.
- Indication
For the prevention of nausea and vomiting associated with initial and repeat courses of emetogenic cancer therapy (including high dose cisplatin), postoperation, and radiation (including total body irradiation and daily fractionated abdominal radiation).
- Associated Conditions
- Nausea and vomiting
- Associated Therapies
- -
A Study of Ramosetron Plus DX, Dexamethasone, Compared to Granisetron Plus DX for the Prevention of Vomiting and Nausea
- First Posted Date
- 2006-01-05
- Last Posted Date
- 2017-03-09
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 287
- Registration Number
- NCT00272285
A Study of Kytril (Granisetron) in the Prevention of Post-Operative Nausea and Vomiting (PONV) in Pediatric Subjects Undergoing Tonsillectomy or Adenotonsillectomy
- First Posted Date
- 2005-10-04
- Last Posted Date
- 2018-03-27
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 171
- Registration Number
- NCT00231478
Phase 2 Trial of Prophylactic Rituximab Therapy for Prevention of CGVHD
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2017-11-28
- Lead Sponsor
- Stanford University
- Target Recruit Count
- 36
- Registration Number
- NCT00186628
- Locations
- 🇺🇸
Stanford University School of Medicine, Stanford, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath